A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer - PubMed (original) (raw)
Clinical Trial
doi: 10.1007/s00280-010-1470-2. Epub 2010 Sep 22.
Kenichi Yoshimura, Masanori Asada, Atsushi Imaizumi, Chihiro Suzuki, Shigemi Matsumoto, Takafumi Nishimura, Yukiko Mori, Toshihiko Masui, Yoshiya Kawaguchi, Kazuhiro Yanagihara, Shujiro Yazumi, Tsutomu Chiba, Sushovan Guha, Bharat B Aggarwal
Affiliations
- PMID: 20859741
- DOI: 10.1007/s00280-010-1470-2
Free article
Clinical Trial
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
Masashi Kanai et al. Cancer Chemother Pharmacol. 2011 Jul.
Free article
Abstract
Purpose: Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy.
Methods: Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy. The primary endpoint was safety for phase I and feasibility of oral curcumin for phase II study.
Results: Twenty-one patients were enrolled. No dose-limiting toxicities were observed in the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the phase II study. No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79-100%). Median survival time after initiation of curcumin was 161 days (95% confidence interval 109-223 days) and 1-year survival rate was 19% (4.4-41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients tested.
Conclusions: Combination therapy using 8 g oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer and warrants further investigation into its efficacy.
Similar articles
- A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT. Chiang NJ, et al. Eur J Cancer. 2020 Jan;124:123-130. doi: 10.1016/j.ejca.2019.10.023. Epub 2019 Nov 22. Eur J Cancer. 2020. PMID: 31765987 Clinical Trial. - TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I. Ioka T, et al. Eur J Cancer. 2019 Jan;106:78-88. doi: 10.1016/j.ejca.2018.10.004. Epub 2018 Nov 22. Eur J Cancer. 2019. PMID: 30471651 Clinical Trial. - Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D, Chen C, Zhou Y, Chen R, Fan X, Bi Z, Li Z, Liu Y. Li D, et al. Medicine (Baltimore). 2015 Sep;94(35):e1345. doi: 10.1097/MD.0000000000001345. Medicine (Baltimore). 2015. PMID: 26334891 Free PMC article. Review. - Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives.
Hosseini M, Hassanian SM, Mohammadzadeh E, ShahidSales S, Maftouh M, Fayazbakhsh H, Khazaei M, Avan A. Hosseini M, et al. J Cell Biochem. 2017 Jul;118(7):1634-1638. doi: 10.1002/jcb.25897. Epub 2017 Mar 15. J Cell Biochem. 2017. PMID: 28106283 Review.
Cited by
- Natural Agents Used in Chemoprevention of Aerodigestive and GI Cancers.
Morris J, Fang Y, De Mukhopdhyay K, Wargovich MJ. Morris J, et al. Curr Pharmacol Rep. 2016 Feb;2(1):11-20. doi: 10.1007/s40495-016-0047-0. Epub 2016 Jan 16. Curr Pharmacol Rep. 2016. PMID: 27134816 Free PMC article. - Efficacy of Polymer-Based Nanocarriers for Co-Delivery of Curcumin and Selected Anticancer Drugs.
Alven S, Aderibigbe BA. Alven S, et al. Nanomaterials (Basel). 2020 Aug 8;10(8):1556. doi: 10.3390/nano10081556. Nanomaterials (Basel). 2020. PMID: 32784356 Free PMC article. Review. - Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.
Irving GR, Iwuji CO, Morgan B, Berry DP, Steward WP, Thomas A, Brown K, Howells LM. Irving GR, et al. Trials. 2015 Mar 24;16:110. doi: 10.1186/s13063-015-0641-1. Trials. 2015. PMID: 25872567 Free PMC article. Clinical Trial. - Knockdown of Ki-67 by dicer-substrate small interfering RNA sensitizes bladder cancer cells to curcumin-induced tumor inhibition.
Pichu S, Krishnamoorthy S, Shishkov A, Zhang B, McCue P, Ponnappa BC. Pichu S, et al. PLoS One. 2012;7(11):e48567. doi: 10.1371/journal.pone.0048567. Epub 2012 Nov 12. PLoS One. 2012. PMID: 23152782 Free PMC article. - Curcumin in Combination with Other Adjunct Therapies for Brain Tumor Treatment: Existing Knowledge and Blueprint for Future Research.
Peter K, Kar SK, Gothalwal R, Gandhi P. Peter K, et al. Int J Mol Cell Med. 2021 Summer;10(3):163-181. doi: 10.22088/IJMCM.BUMS.10.3.163. Epub 2022 Jan 10. Int J Mol Cell Med. 2021. PMID: 35178355 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous